Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients
| Autor: | Elsayed M. Mahgoup, Mohamed F. Abd-Ellah, Magdy A. Gad, Gouda K. Helal |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Hepacivirus Antiviral Agents Gastroenterology Polyethylene Glycols law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Pharmacotherapy Randomized controlled trial Ezetimibe Pegylated interferon law Internal medicine Ribavirin Humans Medicine Single-Blind Method Obesity Prospective Studies 030212 general & internal medicine Prospective cohort study Hepatology business.industry Interferon-alpha Hepatitis C Hepatitis C Chronic Middle Aged Viral Load Virus Internalization medicine.disease Recombinant Proteins Treatment Outcome chemistry Immunology Drug Therapy Combination Egypt Female 030211 gastroenterology & hepatology business Viral load medicine.drug |
| Zdroj: | European Journal of Gastroenterology & Hepatology. 28:553-557 |
| ISSN: | 0954-691X |
| DOI: | 10.1097/meg.0000000000000587 |
| Popis: | BACKGROUND Ezetimibe has been reported to inhibit viral entry and to reduce BMI and has been proposed as a novel therapeutic agent for chronic hepatitis C (CHC), potentiating the effects of pegylated interferon and ribavirin (peg-IFN/RBV). OBJECTIVE The aim of the study was to assess the effects of ezetimibe coadministration with peg-IFN/RBV combination on the early virological response (EVR) rates in nonobese and obese patients with CHC genotype 4 (CHC-4). PATIENTS AND METHODS A total of 144 CHC-4 patients were divided into two groups; group 1 included nonobese patients (n=76) and group 2 included obese patients (n=68). Each group was further subclassified into equal control and treated groups. The control groups received peg-IFN/RBV combination for 24 weeks, and the treated groups received peg-IFN/RBV plus ezetimibe for 12 weeks and then only peg-IFN/RBV for the remaining 12 weeks. RESULTS The study revealed that EVR significantly improved in the obese patients (85.3 vs. 64.7% in the treated and control groups, respectively, at P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|